BONE MARROW FOR MALIGNANCY

Bone marrow transplantation and peripheral blood stem cell treatment for malignancy

Background

The aim of this systematic review was to assess the relative clinical and cost effectiveness of high-dose myeloablative therapy and progenitor cell transplantation (HDT/PCT) compared with conventional therapy for the treatment of malignancy.

Findings

As a whole the review found no conclusive evidence that HDT/PCT is superior to conventional treatment in terms of survival or progression-free survival. Conversely, it has not demonstrated that it is inferior. Given the overall pattern of results, HDT/PCT appears to be a therapy worthy of further exploration.

As few prospective economic analyses were identified it is not possible to determine accurately the comparative cost of HDT/PCT and conventional chemotherapy.

Conducted by: PWM Johnson1, SJ Simnett2, JW Sweetenham3, GJ Morgan4, LA Stewart2

1. ICRF Cancer Medicine Research Unit, St James' University Hospital, Leeds; 2. MRC Cancer Trials Office, Cambridge; 3. CRC Wessex Regional Medical Oncology Unit, Southampton General Hospital; 4. University of Leeds

Further details

Project page on HTA Programme website

Publications

Johnson PWM, Simnett SJ, Sweetenham JW, Morgan GJ, Stewart LA. Bone marrow and peripheral blood stem cell transplantation for malignancy. Health Technol Assess. 1998;2(8)

Funding

Commissioned by the HTA Programme